Tezepelumab reduces mucus plugs in adults with uncontrolled asthma

Health News
Tags :
Health News
Share This :

Tezepelumab reduces mucus plugs in adults with uncontrolled asthma

Tezepelumab is associated with a reduction in occlusive mucus plugs versus placebo in adults with uncontrolled asthma, according to a study published in the October issue of NEJM Evidence.

Lars H. Nordenmark, Ph.D., from AstraZeneca in Oslo, Norway, and colleagues assessed the anti-inflammatory effect of tezepelumab in participants of the CASCADE trial, in which patients (aged 18 to 75 years old) with moderate-to-severe, uncontrolled asthma were randomly assigned (1:1) to 210 mg tezepelumab (37 patients) or placebo (45 patients) every four weeks subcutaneously for at least 28 weeks.

The researchers found that the absolute change from baseline in mean mucus plug score was −1.7 in patients receiving tezepelumab and 0.0 in patients receiving placebo. There was a positive correlation observed at baseline between mucus plug scores and levels of inflammatory biomarkers (blood eosinophils, eosinophil-derived neurotoxin, fractional exhaled nitric oxide, interleukin-5, and interleukin-13), as well as a negative association with lung function measures (prebronchodilator forced expiratory volume in 1 second and forced mid-expiratory flow).

Reductions in mucus plug scores for patients receiving tezepelumab were correlated with improvements in lung function and reductions in blood eosinophil count and levels of eosinophil-derived neurotoxin, a biomarker of eosinophilic degranulation.

“The reduction in occlusive mucus plugs in these patients is consistent with the idea that reducing mucus plugs is a component of the salutary therapeutic effect of tezepelumab,” the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and Amgen, which manufacture tezepelumab and funded the study.

More information:
Lars H. Nordenmark et al, Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma, NEJM Evidence (2023). DOI: 10.1056/EVIDoa2300135

Copyright © 2023 HealthDay. All rights reserved.

Tezepelumab reduces mucus plugs in adults with uncontrolled asthma (2023, September 29)
retrieved 30 September 2023
from https://medicalxpress.com/news/2023-09-tezepelumab-mucus-adults-uncontrolled-asthma.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Popular News Posts


Our Exclusive Products

Our Store

Our mission is simple, offer quality products that make our customers lives better at a reasonable price, while ensuring a hassle-free shopping experience. This means that before we bring a product to market, we test it to ensure that it meets our high-level quality standards. Our customer service team understand our products and can answer most every product related question quickly and efficiently. We strive everyday to meet and exceed our customers’ expectations of quality and support! Should we ever fail to meet this expectation – contact us and we will make it right!

Our Value: We are proud of our product and accomplishments, but we typically don’t shout it from the rooftop. Instead, we prefer to let our product and customers do the talking. Our core values can be recognized in our product. The qualities we strive for include:

Pragmatism: We design simple, useful solutions for common needs
Quality: From design to final product, we strive for durable solutions that work
Originality: Creativity and innovation are what makes our product unique
Design: Our minimalist and bold design language focuses on functionality and simplicity that is timeless

0 +

Top Rated Products

0 +

Happy Customers